As head of research, I utilize my expertise from my time in academia, big pharma, biotech startups and my own consulting firm to lay the groundwork for our company’s future drug discovery methods and breakthroughs. Before joining Beryllium, I founded ALN Associates, a life sciences consultancy. I previously served as the chief scientific officer at Asterand, a global supplier of human tissue and tissue-based research services, and also at Rosetta Genomics, a microRNA-based diagnostic company, where I developed three diagnostic tests based on microRNA. Before that, I worked for 15 years at Novartis and held several executive positions, including vice president and global head of functional genomics. Prior to my work at Novartis, I was a research fellow in oncology at Sandoz Pharmaceutical and the group leader for the development of several compounds. I also served as an adjunct professor at the UMDNJ-Robert Wood Johnson Medical School for 10 years. I am currently a member of ATR’s (Accelerating Translational Research) board of directors, as well as of the advisory boards for Cambridge BioSource, the Massachusetts Life Sciences Center, MassBio’s Forums, Rhenovia and RealBio. I hold a bachelor’s degree in biology, a master’s degree in virology and a doctorate in cell biology from the Faculty of Medicine at Technion, Israel Institute of Technology. I was a postdoctoral fellow at the Albert Einstein College of Medicine.
I truly love science, and it is the lens through which I view the world. I am also transparent – what you see is what you get with me. As a scientist, I am focused on results while also being interested in taking risks. I love working in a team setting for both its energizing capabilities and its motivational powers. I find it invigorating to work in collaboration with several of the best scientific minds in the world to tackle the challenges facing drug discovery.